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Abstract
Background: microRNAs (miRNAs) regulate target genes at the post-transcriptional level and play important roles in cancer
pathogenesis and development. Variation amongst individuals is a significant confounding factor in miRNA (or other)
expression studies. The true character of biologically or clinically meaningful differential expression can be obscured by
inter-patient variation. In this study we aim to identify miRNAs with consistent differential expression in multiple tumor
types using a novel data analysis approach.
Methods: Using microarrays we profiled the expression of more than 700 miRNAs in 28 matched tumor/normal samples
from 8 different tumor types (breast, colon, liver, lung, lymphoma, ovary, prostate and testis). This set is unique in putting
emphasis on minimizing tissue type and patient related variability using normal and tumor samples from the same patient.
We develop scores for comparing miRNA expression in the above matched sample data based on a rigorous
characterization of the distribution of order statistics over a discrete state set, including exact p-values. Specifically, we
compute a Rank Consistency Score (RCoS) for every miRNA measured in our data. Our methods are also applicable in
various other contexts. We compare our methods, as applied to matched samples, to paired t-test and to the Wilcoxon
Signed Rank test.
Results: We identify consistent (across the cancer types measured) differentially expressed miRNAs. 41 miRNAs are under-
expressed in cancer compared to normal, at FDR (False Discovery Rate) of 0.05 and 17 are over-expressed at the same FDR
level. Differentially expressed miRNAs include known oncomiRs (e.g miR-96) as well as miRNAs that were not previously
universally associated with cancer. Specific examples include miR-133b and miR-486-5p, which are consistently down
regulated and mir-629* which is consistently up regulated in cancer, in the context of our cohort. Data is available in GEO.
Software is available at: http://bioinfo.cs.technion.ac.il/people/zohar/RCoS/
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Introduction
Gene expression profiling is commonly applied to identify
differences between classes of cell types, as manifested in differentially
expressed genes [1–4]. A typical dataset comprises tens of samples in
which the expression levels of thousands of genes are measured. In
classified expression data the set of samples is partitioned into
different subsets or classes based on prior knowledge, such as normal
samples vs. tumor samples or samples of different cancer types.
Similarly, it may be partitioned into different conditions, different
stages, or different therapy related categories. Most of the current
data analysis literature focuses on considering the entire dataset in the
process of identifying differentially expressed genes. Various types of
genomic variation are significant and often ignored confounding
factors in differential expression studies. For example, in Shyamsun-
dar et al. [5] the authors survey messenger RNA expression level
variation in normal human tissues, showing the potential confound-
ing effects of inter-tissue variation.
It would be valuable to identify statistically significant
differences in various samples that can be reliably attributed to
the specific biological state, such as cancer or disease, instead of
individual biological variations, as stated above. In many
situations, there is opportunity for serial collection of tissue or
blood from a patient, experimental animal or cell line [6,7].
However, many current analysis techniques do not exploit the
unique relationships within such data. In other cases, class or
patient variability can mask differential expression and needs to be
addressed. In this study we analyze matched samples to investigate
tumor vs. normal differential expression, which is consistent for
multiple tumor types, and describe suitable and robust statistical
methods that support this investigation.
Currently, hundreds of microRNAs (miRNAs) have been
identified in humans. These are short (usually about 22-nt)
noncoding regulatory RNA molecules and their sequences are
published in the Sanger miRBase [8]. miRNA expression profiling
has been recognized to provide valuable biological information
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miRNAs regulate target genes at the post-transcriptional level and
play important roles in development as well as in cancer [9–11]
and in other human diseases, including heart disease [12–14],
schizophrenia [15] and psoriasis [16]. miRNAs are highly
differentially expressed in different tissue types [10]. Therefore,
to identify miRNA differential expression due to specific
conditions we need to minimize the confounding effect of the
above tissue dependent differential expression.
Our goal in this study is to identify miRNAs that are consistently
differentially expressed in multiple cancer types. To avoid tissue
type variability and to measure cancer related differential miRNA
activity in each type separately; we use a matched sample dataset
consisting of 32 microarray measurements representing 28
matched tumor and normal samples. We use microarrays
containing probes for 799 miRNAs to profile miRNA expression
in these samples.
Our motivation in seeking miRNAs with consistent differential
expression in multiple cancer types stems from the existing
knowledge that many biological processes are common to different
types of cancers. In particular, several genes are known to be
universally differentially expressed across multiple cancer types.
The most obvious example is p53. p53 was first discovered in 1979
and since then numerous studies indicated its involvement in
multiple cancer types. The importance of regulated activity of
intact p53 in preventing tumor formation is indicated by the
presence of mutations in the p53 pathway in nearly all cancers
[17,18]. Another example of a universal cancer related protein is
p16. This gene resides on chromosome 9 and was found to be
mutated or deleted in multiple cancer types [19–22]. These are
only two specific examples, amongst a large variety of cellular
processes that are universally associated with cancer.
Previous studies on the role of miRNAs in cancer include Lu
et al. [9] who performed a tumor vs. normal cross-tissue analysis
using bead-based flow cytometry technology in a non-paired
manner. This study showed that miRNAs are sufficient to
accurately classify cancer tissues according to their embryonic
lineage, giving global characteristics of miRNA expression in
cancer. Another study, by Volinia et al.[10], described microarray
measurement of 228 miRNAs in 540 samples (363 cancer and 177
normal) from 6 different tissue types. In addition to producing
miRNA signatures, the authors reported some miRNAs that are
consistently over or under expressed, but there was no detailed
statistical benchmarking for the consistency of miRNA differential
expression. The authors state that when clustering their data in an
unsupervised manner, the samples cluster based on the tissue
types, irrespective of the disease status, reflecting the high variation
of miRNAs when comparing tissue types. This reinforces our
assertion above, that points to miRNA inter-tissue-type basal
variation as a confounding factor when seeking to measure
miRNA cancer differential expression. Several other studies focus
on miRNAs in specific cancer types. For example, mir-15 and mir-
16 are frequently deleted and/or downregulated in B-cell chronic
lymphocytic leukemia [23], miR-143 and miR-145 show de-
creased expression in colorectal neoplasia [24], and miR-155 is
up-regulated in human B cell lymphomas [25].
To support our research goals we have developed statistical
methods that address characterizing distributions of random
variablesthatarisefrom comparingmatched samples. Inour case
we compute differential expressi o ni ne v e r yt u m o rt y p ea n dt h e n
statistically assess its prevalence in our dataset. Our methods are
based on discrete order statistics – the k-dimensional vector that
is obtained by drawing k independent numbers uniformly in
1…N and then sorting them resulting vector. While the
distribution of order statistics over continuous state spaces is
well characterized, this is not the case for discrete sample spaces
as repeats may then occur with positive probability. Computing
distributions related to discrete order statistics was addressed in
[26]. For our needs we define random variables over discrete
order statistics, fully characterize their distributions and then
apply the methods to the biological data to assess statistical
significance.
To summarize, the contribution of this paper consists of:
N Rigorous characterization of the distribution of order statistics
over a discrete state set as well as of related random variables.
This distribution is highly applicable in analyzing matched
data in a non parametric setup. We also compare our methods
to paired t-test and to the Wilcoxon Signed Rank test.
N A dataset with matched tumor normal samples representing a
repertoire of 8 tumor types. This set is unique in its emphasis
on minimizing the tissue type and patient related variability
through the use of normal and tumor samples from the same
patient.
N By applying the novel statistics described above to our
matched sample dataset we validate known oncomiRs and
describe several novel cancer-universal differentially expressed
miRNAs. It should be noted that this stated universality is only
substantiated, within the context of this study, for the 8 types
represented here.
Methods
The starting point for analyzing the results of a gene or miRNA
expression profiling study is the expression raw data matrix. When
describing the methods we use the word ‘‘gene’’ but ‘‘miRNA’’
can be used interchangeably. This matrix is typically the output of
several pre-processing steps such as normalization and filtering
performed on the raw measurement data.
Typically, data analysis of expression profiles starts with the
identification and the statistical assessment of genes that are
differentially expressed when comparing various classes represent-
ed in the cohort. Many current gene scoring methods consider all
expression values of a given gene. These are partitioned into two
or more populations according to the studied classification.
Differences between the resulting subsets of numbers are assessed
using various statistical methods. Gene scoring methods fall into
two broad categories – parametric methods, and non-parametric
(distribution free) methods. Parametric methods assume a certain
distribution for the expression values of every gene within each
given class (e.g. cancer or normal) and then score genes according
to how separate the class specific distributions are. Examples of
such methods are the standard t-test [27] and the Gaussian Error
score [28]. Distribution free scores, in contrast, are not based on
parametric assumptions. These include the Kolmogorov-Smirnov score
[29], and the Wilcoxon Rank-Sum test [30] as well as the Information
score [31] and Threshold-Number-of-Misclassifications (TNoM in short)
[31]. The latter nonparametric methods were applied to gene
expression and other genomic and genetic data in several studies,
as in [2,32–35].
This work is concerned with additional and potentially more
relevant information that can be inferred when the expression data
is coming from several patients and when all classes were
measured for each patient. For example, samples before and after
treatment for the same patient. Another example is tumor and
normal samples from the same tissue of each patient, a design
utilized in this work. The scores we develop take into account the
Cancer miRNA Rank Consistency
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patients. The interpretation is that a gene is relevant to the
underlying biology if it is highly differentially expressed for most of
the patients. In addition, we attach a significance level (p-value) to
each relevance score level. The p-value is the probability to get this
level or better, at random, as described below in further detail.
Rigorous statistical analysis is instrumental in confidently identi-
fying genes that sharply separate sample classes and thus in
pointing at promising research directions. Partial variants of the
methods described in this paper were employed in [6] and in [36].
It is particularly important to work with matched statistics when
analyzing miRNA expression data, as basal level for these may be
highly variable, especially in distinct tissues [10].
In this section we describe the statistical methods in high
generality. Specific embodiments, in the context of consistent
tumor versus normal miRNA differential expression, are described
in the Results Section.
Rank Consistency Score (RCoS)
The Rank Consistency Score (RCoS) is a differential expression
score for 2 classes that takes patient matching into account.
We call the two classes Class A and Class B. We first compute
the differential expression between the two classes for every patient
(or subject or subset) k=1…r and for every gene g. The differential
expression can be calculated using different methods and the
method chosen depends on the design of the study and on the
number of samples for each patient. Differential expression scores
include: fold change, Gaussian error score, t-test, TNoM and other
methods. Often the number of samples for each patient and class is
1, so simple fold change is used.
Next, we rank all the genes per patient according to their
differential expression between class A and class B. For every gene
g we compute its rank for the k-th patient: Rk(g) – this is a number
between 1 and N, where N is the total number of genes. The gene
gtop for patient k is the one most over-expressed in Class A relative
to Class B. It is ranked first and we set Rk gtop
  
~1. The rank of
the gene most under-expressed in the Class A relative to the Class
Bi sN.
Our goal is to find genes with consistently high ranks (of
differential expression between class A and class B) across all
patients. For every gene g, we define the rank consistency score
S(g;r) as the normalized maximal rank of this gene among all
patients, i.e.
Sg ;r ðÞ ~max1ƒkƒrRk g ðÞ =N:
In other words, the rank of gene g for all patients is no worse
than S(g;r)?N.
For greater flexibility in defining consistency we allow outliers,
and compute the rank consistency scores S(g;m) for m out of r
patients. In this case for each gene we order its ranks and then the
score S(g;m) corresponds to the normalized m-th smallest rank:
Sg ;m ðÞ ~The m{th smallest Rk g ðÞ =N, where 1ƒkƒr:
We call the m out of r rank consistency score, S(g ;m), the m/r
RCoS. We will sometimes refer to the r/r RCoS simply as RCoS.
Figure 1 illustrates the definition of various m out of r rank
consistency scores. Pseudo-code for calculating the m/r RCoS is
available at Text S1.
The above analysis will identify genes that are over-expressed in
Class A compared to Class B. To find genes over-expressed in the
Class B we can perform the same analysis, reversing the ranked
list.
To evaluate the statistical significance of any observed value of
RCoS we estimate the probability of obtaining the value s, or
better, in random data drawn according to a null model. This
probability is the p-value corresponding to this level s, under the
prevailing null model. The p-values for RCoS and for its variants
considered in this paper are computed under the assumption of
independence of patients and of uniform distribution of ranks
among genes within each patient. These two assumptions define
the underlying null-model.
To compute the m/r RCoS p-value at s, we compute the
probability of a gene ranking in the top s fraction of the list, in at
least m patients. Let V be an r-dimensional random vector with
entries drawn independently and uniformly in 1,…,N. We are
interested in the probability of the m-th smallest entry in V being
smaller than sN. It is given by:
p{Val(s,m)~
X r
k~m
r
k
  
sk(1{s)
(r{k)
Minimum Rank Consistency Score (minRCoS)
When working with larger sample sets the question of how
many outliers to allow (which m to choose) arises. A possible
principled solution is to calculate the m/r RCoS p-value for all
possible values of m and choose the value of m with the best p-
value. This p-value must of course be corrected for multiple
testing. In this section we define the minimal-rank-consistency
score, and show how to efficiently characterize its distribution,
enabling the calculation of p-values (with no further need for
multiple testing correction). We first describe the calculations and
then analyze its total time complexity.
Figure 1. Illustration of Rank Consistency Score. In each of the 5
patients/groups in this example, ranks of the genes change from 1 to
1000. Each column represents a ranked list for one group. The gene
chosen for the example has the worst among 5 groups rank of 200.
Therefore, its rank consistency is score 200/1000=0.2; its rank
consistency score in 3 out of 5 patients is 95/1000=0.095 as indicated
by the arrows.
doi:10.1371/journal.pone.0008003.g001
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[N]; Let [N]
r represent the set of vectors of length r, where each
entry is from [N]. We use V to denote a random vector uniformly
distributed over [N]
r.
Given a vector v[ N ½ 
r we denote the m-th smallest number in v
by v,m.. That is, vv1wƒvv2wƒ ... ƒvvrw. Given an index
m[ r ½  , and a rank t[ N ½  , we denote by b(m,t) the probability that
V,m. will equal t or less. Note that b(m,t) is the p-value, at s=t/N,
of m-out-of-r rank consistency score defined previously, and can
be efficiently computed as shown in the previous section.
We define the minimal rank consistency score of a vector v, denoted
by mRCoS(v), by mRCoS v ðÞ ~minm~1,::,r b(m,vvmw) fg . In words,
mRCoS(v) is the best (minimal) rank consistency p-value, where m
varies from 1 to r. mRCoS(V) is therefore a random variable taking
values in [0,1]. We now compute the exact p-value associated with
mRCoS(V) at a given value, p:
pValmRCoS(p)
~Pr(mRCoS(V)ƒp)
~Pr(minm~1,...,rfb(m,Vvmw)gƒp)
~Pr(Am[½r  : b(m,Vvmw)ƒp)
~1{Pr(Vm[½r  : b(m,Vvmw)wp):
Given p[ 0,1 ½  , and an index m~1,::,r, define tm p ðÞ to be the
minimal rank t such that b m,t ðÞ wp. Note that since we can
efficiently compute b(m,t) for all m[ r ½  and t[ N ½  , we can
efficiently ‘‘invert’’ b(m,t) and compute tm(p). Note that
t1 p ðÞ ƒt2 p ðÞ ƒ...tr p ðÞ . Using the above notation we have:
Pr(Vm[½r  : b(m,Vvmw)wp)~Pr(Vm[½r  : Vvmw§tm(p)):
Given a constant ranks vector C, we say that a vector vM[N]
r is C-
bounded if vvmw§Cm (for all m=1,..,r). In words, all sorted entries
of v are larger (or equal to) the corresponding entries of C. For
example, the vector v=,3,2. is bounded by C~ v1,3w, since
vv1w~2§1~C1,vv2w~3§3~C2.
The total number of vectors in [N]
r that are C-bounded is
denoted by B(N,r,C).
For example, for N~3, r~2,
N ½ 
r~ 3 ½ 
2~
v1,1w,v1,2w,v1,3w,v2,1w,v2,2w,v2,3w,v3,1w,v3,2w,v3,3w fg :
The set of vectors bounded by C~ v1,3w is
v1,3w,v2,3w,v3,3w,v3,1w,v3,2w fg , and therefore
B 3,2,v1,3w ðÞ ~5.
By the definition of B(N,r,C), since V is chosen uniformly at random,
we get Pr(Vm[ r ½ : Vvmw§tm p ðÞ )~BN ,r,t p ðÞ ðÞ =Nr,w h e r et(p)
denotes the vector vt1 p ðÞ ,t2 p ðÞ ,...,tr p ðÞ w. Therefore, we have
reduced the problem of computing a p-value for the minimal-rank-
consistency score to the combinatorial problem of efficiently computing
how many vectors in [N]
r are bounded by a given vector C~t p ðÞ .
Computing B(N, r, C)
Given two integers, N, r, and a vector C, we want to compute
B(N,r,C), the number of C-bounded vectors in [N]
r. For each vector
v we define two properties: t(v) and k(v).
N t(v) is the maximal entry of v. That is, tv ðÞ ~vvrw. Note that
t(v) can assume the values 1 through N.
N k(v) is the number of entries in v whose value is strictly smaller
than t(v). Note that k(v) can assume the values 0 through r21.
These two properties can be used to partition [N]
r.
We denote the set of all C-bounded vectors for which tv ðÞ ~t
and kv ðÞ ~k by L C,t,k ðÞ . Note that these sets are indeed disjoint,
and that their union covers all C-bounded vectors. By using
L(C,t,k) we can compute B(N,r,C), summing over all possible
values of t and k:
B(N,r,C)~
X
t~cr,...,N
X
k~0,...,r{1
L(C,t,k)
As there are only N*r such sets this would yield an efficient
procedure to compute B(N,r,C). We use a dynamic programming
approach to compute all N*r values.
Let C(1..k) be the first k elements of C, that is
C 1::k ðÞ ~vC1,C2,...,Ckw. We note that in a vector
v[L(C,t,k) the (r-k) largest ranks equal t. Therefore, to compute
jL(C,t,k)j we need only determine the positions within v of the k
smallest values, and their actual values, such that they are all
strictly smaller than t, and are C(1..k) bounded:
L(C,t,k) jj ~
r
k
  
B(t{1,k,C(1...k))
We now use the following dynamic programming procedure to
compute the number of C-bounded vectors:
B(N,r,C)~
1 if r~0
P
t~cr,...,N
P
k~0,...,r{1
r
k
  
B(t{1,k,C(1 : k)) otherwise
8
> <
> :
This enables us to efficiently compute the minRCoS p-value:
pValmRCoS(p)~1{
B(N,r,t(p))
Nr
There are a total of N*r dynamic programming steps needed to
calculate B(N,r,C). In each step, calculating B(t,k,C) requires
summing over t*k values of B. In total the complexity of the
dynamic programming procedure to compute B(N,r,C) is therefore
O(N
2*r
2). To compute C~t p ðÞ we need to perform a maximum
of r*N RCoS p-value calculations, each one taking O(r).
Therefore, the complexity of the minRCoS p-value calculation
for a given p is O(N
2*r
2).
Samples, Experimental Protocol and Data Pre-Processing
The data were collected from adjacent tumor-normal total
RNA samples purchased from Ambion/ABI (FirstChoiceH
Human Tumor/Normal Adjacent Tissue RNA). The matched
pairs of tumor and normal RNAs were from 14 different patients
and 8 different cancer types. Tissue samples were of various
embryonic lineages: One pair from breast, lymphoma, and
prostate; two pairs from liver, ovary, testes and lung; and 3 pairs
Cancer miRNA Rank Consistency
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testes samples, thus a total of 32 microarray data were used for this
study.
For each microarray measurement, 100ng total RNAs were
labeled with Cy3 using T4 RNA ligase per Agilent miRNA
Micorarray Systems Protocol v1.5. The labeled RNA samples
were hybridized onto Agilent miRNA microarray (Agilent Human
miRNA Microarray kit V2 - G4470B) for 21 hours at 55C. The
arrays contain probes for 723 human and 76 human viral miRNAs
from the Sanger database v.10.1. The arrays were then washed at
room temperature and scanned to produce the hybridization
signals (Agilent miRNA Micorarray Systems Protocol v1.5). The
arrays were scanned with extended dynamic range at 5 and 100%
PMT using the Agilent scanner (model G2565AA).
Agilent’s Feature Extraction software version 9.5.3.1 was used to
generate GeneView files [37]. These files contain the processed
signals for each of the 799 miRNAs on the array. For each miRNA,
expression values (gTotalGeneSignal) below the noise level
(gTotalGeneError) were replaced by the value of the corresponding
total gene error. All samples were then normalized to have the
same 75
th percentile value. The raw and normalized data have
been deposited in NCBI’s Gene Expression Omnibus [38] and
are accessible through GEO Series accession number GSE-
14985 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE14985). All data is MIAME compliant. The normalized data
are also available in Table S1.
Results
We applied rank consistency scoring methods to data collected
in a study of miRNA expression profiles in cancer related samples.
Data collected in this study consisted of paired samples of tumor
and normal origins. Each pair of samples was taken from different
parts of the same tissue in 14 different patients and 8 different
cancer types: breast, colon, liver, lung, lymphoma, ovary, prostate
and testis. The matched pairs of samples enable us to focus on
changes in miRNA expression levels that result from the cancer
process and to minimize the confounding effect of inter-individual
and inter-tissue variability.
The goal of the study was to identify miRNAs universally
differentially expressed in cancer using the statistical methods and
measurements described above.
We computed the tumor vs. normal differential expression of
each miRNA in the data in four different ways: TNoM [31], non
paired t-test, paired t-test and minRCoS. For the first three
methods, signals were log transformed and in cases where more
than one patient exists per cancer type the median was used. The
TNoM and unpaired t-test were computed for non-paired
comparison of all tumor samples to all normal samples. For the
paired t-test the cancer type matching was used.
For the different variants of RCoS (m/r RCoS and minRCoS),
fold change was calculated for each miRNA and patient by
dividing the tumor signal by the normal signal. In cancer types
where more than one patient exists (2 or 3 patients) the median of
the fold changes was used. This was done to preserve the patient
matching (within the same cancer type) in our data. For each
cancer type the miRNAs were then ranked according to these
values to generate the ranked lists needed as the input to all the
RCoS variants. The application of the general framework
described in the Methods section to our dataset therefore leads
to the following semantics:
N Class A and class B are tumor and normal.
N r=8.
N If for a miRNA, denoted g, we have, for example, 6/8
RCoS(g)=0.2 for over-expression in tumor vs. normal, then
this miRNA is ranked amongst the top 20% of miRNAs over-
expressed in tumor vs. normal, for at least 6 out of the 8
different tumor types. Obviously, similar interpretations hold
true for other values of m and s (6 and 0.2 respectively, in the
example above).
The complete set of results of our analysis, including all the
differential expression scores and the associated p-values, is
available as supplementary material (Table S2).
To apply the paired t-test on these data, fold change was
calculated for each miRNA and patient by dividing the tumor
signal by the normal signal. In cancer types where more than one
patient exists the median of the expression values was used in the
fold change calculation. The data was then log-transformed to
achieve the normality required by the paired t-test. We note that
even after the log-transformation, the hypothesis of normality of
this distribution is rejected by the Jarque-Bera test [39].
The observed and expected numbers of genes for all minRCoS
p-values and the levels at which FDR (False Discovery Rate) [40]
and Bonferroni of 0.05 are obtained are shown in Figure 2. Note
the specific overabundance of differentially expressed miRNAs, as
compared to random data expected numbers.
A heatmap of the most significant miRNAs identified by
minRCoS analysis is shown in Figure 3. The right panel contains
the top 30 miRNAs whose expression levels are consistently
increased in cancerous tissues; the left panel contains a list of the
top 30 miRNA whose expression levels are consistently decreased
in cancerous tissues. Specific conclusions and findings of the
analysis are described below, including miRNAs that were not
previously universally associated with cancer.
Differentially Expressed miRNAs Found by RCoS and Not
by Other Methods
Some of the miRNAs we observe as differentially expressed
were identified as significantly differentially expressed both by
matched and by non-matched analysis. For example, miR-96
which is discussed in detail below was found by all four methods
described above.
In contrast to miR-96, other miRNAs were detected by
minRCoS and not by other methods (both matched and non-
matched). An example of such a miRNA which is also not
reported in previous multi-type cancer datasets [9,10] is miR-
133b.
miR-133b receives 7/8 RCoS of 0.048 (p=5*10
29) and a
minRCoS p-value of 10
28. A close inspection reveals that,
excluding the liver sample, miR-133b is under-expressed in all
tumor types, compared to the corresponding matched normal
tissue. Interestingly (see Figure 4), the miR-133b basal expression
values are highly tissue-type variable. Indeed TNoM and t-test do
not find a significant separation between the classes. This is an
example of the tissue-type variability of miRNA, as noted in the
Introduction. miR-133b is also not detectable by paired-test since
the paired t-test is greatly affected by the outlier, namely the liver
sample. miR-133b was recently found, using RT-PCR, to be
consistently down regulated in colorectal cancer by Bandres et al
[41]. The authors further show that known proto-oncogenes, like
YES1 and MAP3K3, are targeted by miR-133b. We note that
since human miR-133a and 133b are highly homologous, differing
by only one nucleotide, there could be some cross hybridization in
hybridization-based measurements. Cross hybridization in the
platform used in our study was shown to be very low by Wang
et al. [42], where the authors demonstrate the platform’s ability to
Cancer miRNA Rank Consistency
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e8003Figure 2. Overabundance analysis of rank consistency. The top plot shows comparison of observed and expected counts of miRNAs for
minRCoS p-values. For each p-value (on the x axis), the expected number of miRNA that have this, or better, p-value based on the total number of
miRNA on the array, is shown in blue (similar to [54]). The red and green lines symbolize the number of observed miRNAs in our data with these
minRCoS p-values. The bottom panel shows a comparison of observed and expected counts of genes with minRCoS p-values of 0.003 or less (a
zoom-in on the top panel). Line A indicates the Bonferroni threshold of 0.05, line B indicates the FDR [40] threshold of 0.05 for the over-expressed
miRNAs (17 miRNAs) and line C indicates the FDR threshold of 0.05 for the under-expressed miRNAs (41 miRNAs).
doi:10.1371/journal.pone.0008003.g002
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family.
miR-143 is another example of a miRNA which would not have
been found by other methods. When ranking all measured
miRNAs using unpaired t-test it ranks as number 70, and when
using a paired t-test it ranks as number 59 with a p-value of 0.04.
However, when ranking the miRNAs using minRCoS it is ranked
as number 11 with a minRCoS p-value of 7*10
26 (Figure 3, left
panel). miR-143 is known to be under-expressed in several
different cancer types as described in [43-45,24].
miRNAs Over-Expressed in Cancer Compared to Normal
The top ranking over-expressed miRNA in cancer based on
minRCoS ranking is miR-96. It is over-expressed in all 8 cancer
types and has a minRCoS p-value of 10
28. miR-96 was found to
be consistently up regulated, validated by RT-PCR, in colorectal
cancer [41]. miR-182 and miR-183, which reside in the same
cluster with miR-96, on Chr7q32 are both over-expressed in our
cancer samples. This leads to the hypothesis that the entire cluster
is amplified in cancer. Indeed, Zhang et al [46] show that the locus
containing miR-182 is amplified in 28.9% of their ovarian cancer
samples. They also state that forced expression of mir-182 in
ovarian cancer cell line, significantly promoted tumor growth in
vivo, confirming the role of miR-182 as a putative oncogene.
The second top ranking cancer-universal over-expressed
miRNA based on minRCoS ranking is miR-629*. It is over-
expressed in all 8 cancer types and has a minRCoS p-value of
10
27. Little is known about this miRNA, and it was not measured
by previous multi-type cancer datasets [9,10]. Mitchell et al [47]
compared miRNA serum levels between 12 mice with human
prostate cancer xenografts and 12 controls. They found that mir-
629* is greatly over-expressed in the xenograft mice plasma. They
therefore hypothesize that miR-629* is potentially secreted from
the xenograft cells.
Figure 3. A heatmap of the top ranked miRNAs according to minRCoS analysis. Columns represent cancer types and the rows represent
miRNAs. A green entry represents a miRNA with a very high rank i.e. one which is under-expressed in this specific tumor sample compared to the
matched normal sample. A red rectangle indicates a miRNA over-expressed in the tumor sample. The left panel shows the top 30 miRNAs universally
under-expressed in tumors ranked according to minRCoS analysis and the right panel shows the top 30 miRNAs universally over-expressed in tumors
ranked according to minRCoS analysis.
doi:10.1371/journal.pone.0008003.g003
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13 (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-
92a-1) are part of the top 30 over-expressed miRNAs. This
polycistron is a known oncogene in several cancer types
[10,48,49].Most members of the miR-17 family (which highly
overlaps this cluster) are also in this list.
miRNAs Under-Expressed in Cancer Compared to Normal
The top ranking under-expressed miRNA in cancer based on
minRCoS ranking is miR-486-5p. It is under-expressed in all 8
cancertypesand has a minRCoSp-valueof 10
29. miR-486-5p (along
with miR-451 which is also under-expressed in our data) was recently
found to be down regulated in Glioblastoma stem cells (CD133+)
compared to non-stem (CD1332) cells [50]. CD133+ cells initiate
and propagate tumors unlike CD1332 cells [51]. miR-133b which is
the second top under-expressed miRNA is discussed above.
Applying Our Methods to a Literature Dataset
We also applied our methods to the Lu et al [9] dataset, as
follows. 84 samples from 7 different cancer types (colon, breast,
lung, prostate, kidney, bladder and uterus) were used from the Lu
et al dataset. These represent all solid tumor types that have at
least 2 tumor samples and 2 normal samples. The first 4 types were
also measured in our study. For each of the 7 cancer types all 217
miRNAs measured by Lu et al were ranked according to their
differential expression between tumor and normal samples, in a
given type, using unpaired t-test. We then looked for miRNAs
consistently over or under expressed across most tumor types using
minRCoS (r=7). The list of all 217 miRNAs measured in the Lu
et al study and their p-values is provided in Table S3.
When searching for over-expressed miRNAs we find, for
example, consistent high ranks for miR-182 and miR-183(min-
RCoS p,10
27, see Table S3). These miRNAs and their cluster
have been previously shown to be over-expressed in cancer and
are also detected as such for our dataset, as discussed previously. In
addition to detecting the over-expression of miR-182 and miR-183
in Lu’s data, we also found more highly concordant results such as
significant under-expression of miR-1, miR-195 and miR-99a in
both datasets, analyzed using the methods of this study (Table S3).
Discussion
Our unique dataset, designed to minimize tissue type con-
founding affects, combined with our novel approach to rank order
statistics in discrete random variables enabled us to produce novel
findings associating certain miRNAs to universal cancer related
processes. Most notably we demonstrate differential expression in
a majority of 8 tumor types for miRNAs which were previously
only indentified in the context of specific cancer types:
N miR-133b - previously shown to be down regulated in colon
cancer [41].
N miR-486-5p - previously shown to be differentially expressed
in Glioblastoma [50].
N miR-629* - previously shown to be secreted into the plasma of
xenograft bearing mice [47].
The findings of this paper address processes that are common
amongst various types of cancer. This is, in some sense, orthogonal
and complementary to other miRNA studies [52,53] that focused
on finding differences between different cancer types. miRNA
Figure 4. Log signal values of miR-133b. Blue diamonds represent tumor samples and magenta triangles represent normal samples. Note that
there is no single threshold that separates all normal samples from all tumor samples. It is also clear that in all but one type (liver) miR-133b is under-
expressed in the tumors. This is an example of a differentially expressed miRNA detected by RCoS and not by un-matched analysis nor by paired t-
test.
doi:10.1371/journal.pone.0008003.g004
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Lu et al [9] and Volinia et al [10] as described in the introduction.
The current study takes a more statistically refined and accurate
approach, providing rigorous statistics and enabling the identifi-
cation of differentially expressed miRNAs. The study design and
our statistical methods allow us to conclude that this differential
expression is a reflection of biological state, such as cancer, instead
of as reflection of biological identity, such as liver vs. lung.
Traditional approaches to matched-pairs analysis include:
N Paired t-Test: t-Test applied to the difference between matched
measurements.
N Wilcoxon Signed Rank Test: when the differences are not
normally distributed, a non parametric method such as a
Wilcoxon Signed Rank Test is applied to the differences.
N SAM- statistics implemented within SAM [34] for paired
analysis. SAM uses permutation testing to assess score
significance.
These approaches suffer from the following shortcomings. The
t-test is only applicable for normally or close to normally
distributed data. In expression data, specifically in miRNA
expression, this is often not the case. In addition, the paired t-
test requires ranking in each group be performed using fold-
change. When ranking genes in each group using a non-paired t-
test for example, the paired t-test is no longer applicable. Under
the Wilcoxon Signed Rank Test a gene that is always higher in the
tumor samples but very slightly so will score better than one that is
higher by a large margin in all patients but one and is just slightly
lower in that outlier. For example, when ranking all miRNAs in
our cohort as discussed in the results section the ranks of miR-
133b are ,10, 4, 6, 1, 16, 770, 26, 39. and the ranks of miR-582-
3p are ,345, 355, 368, 205, 356, 218, 357, 95.. Because of the
low rank of miR-133b in the liver sample, miR-582-3p will score
better when using the Wilcoxon Signed Rank Test. We attribute
more biological significance to the differential expression of miR-
133b since miR-582-3p has a close to median behavior in all
tumor types. The third method discussed, SAM, uses permutation
testing to assess score significance and therefore is less applicable
for cases with small numbers of patients such as the dataset used in
this study. Permutation testing also limits the p-values by the
number of permutations performed.
Combinatorial methods for analyzing matched expression data
are useful in discovering effects that are not necessarily evident
when working with statistical scores that don’t take the sample
matching into account. Generally, when a gene manifests a robust
fold change when comparing two clinically different sets of
samples, then the same will hold true when the analysis is
performed using the matched structure. The opposite is not true.
We identified several miRNAs that are clearly differentially
expressed as a result of tumor related processes. These miRNAs
could not be identified if one ignores the sample matching
information. Determining and statistically assessing the differential
expression by comparing expression levels in two different
conditions in the same patient serves to offset inter-patient
variation that exists in such data. Combinatorial methods have
an advantage over parametric methods especially in small sample
sets and in studies where we cannot impose model assumptions,
such as normality of the underlying distributions.
A good example for the utility of our method is seen when
applied to the data generated by Lu et al [9]. In this study the
research team profiled the miRNA expression in 334 samples and
established a pioneering dataset for the study of global miRNA
differential expression in cancer. One of the main conclusions of
Lu et al was that the overall expression level of miRNAs is down
regulated in tumors relative to the normal samples. Moreover, the
miRNAs that were specifically identified by the study as
differentially expressed in cancer were shown there to be down
regulated in cancer. This apparent absence of miRNAs that are
up-regulated in cancer has been challenged by later studies
[10,11]. Since our approach is based on ranks instead of on the
actual expression values of miRNAs in each cancer type, the
RCoS method also detects miRNAs that are up regulated in
cancer, such as miR-182 and miR-183, in Lu et al’s data. This
example illustrates how RCoS can offset possible biases frequently
encountered in the experimental data.
Our statistical methods are not limited to matched samples
scenarios, nor to miRNA and cancer. They are applicable to other
comparison contexts as well. To be applicable the input data
should contain ranking of all elements (such as genes or miRNAs)
for each group (such as a patient). This ranking reflects a quantity
of interest that was computed or measured in each group, such as
the extent of differential expression. The methods will find
elements with consistent high ranks across all (or most) of the
groups. Software for computing this is available at: http://bioinfo.
cs.technion.ac.il/people/zohar/RCoS/
The concordance of the findings of our study with the findings of
several other studies and the use of RCoS on the Lu et al data are
strongly supportive of the cancer-universal nature of the differential
expression of several known cancer-associated miRNAs, namely:
miR-133, miR-96 and miR-182. Importantly, this concordance
demonstrates the utility of our statistical methodology for analyzing
data from different platforms and multiple cancer types. Also, it
lends confidence in the miRNAs identified here as differentially
expressed in cancer. Thus, in addition to identifying the already
known cancer-associated miRNAs mentioned above, our method
has identified two novel cancer-associated miRNAs, namely miR-
486-5p and miR-629*. As we tested multiple tumor types, these
appear to be novel cancer-universal miRNAs.
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